Omalizumab in cold urticaria in children: Retrospective case series of 13 patients, review of the literature

Briand, C.; Tétart, F.; Soria, A.; Staumont‐Sallé, D.; Sterling, B.; Boralévi, F.; Lakkis, Farah; Du-Thanh, A.; Raison‐Peyron, Nadia; Chiavérini, C.

doi:10.1016/j.annder.2021.08.002

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twelve patients showed clinical improvement and safety was also excellent. 42 All of these studies demonstrate high safety and effectiveness of omalizumab therapy in pediatric CU populations, with responding rates similar to the adults. 43 , 44 , 45 In future studies, sufficient number of children with age younger than 12 years should be included to evaluate the efficiency and safety on the younger pediatric populations.…”

Section: Application Of Omalizumab In Children’s Allergic and Related Diseasesmentioning

confidence: 87%

Pediatric usage of Omalizumab: A promising one

Zhang

Pan

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

Allergic and related diseases have a substantial epidemiological impact on the pediatric population. Small molecule-based medicines have been traditionally used to manage the diseases. Omalizumab is the first monoclonal antibody-based medicine used in children's allergy and shows great promises. It binds to free IgE and prevents it from binding to IgE receptors, thus interrupting the IgE-dependent allergic inflammatory cascade. Vast amounts of data demonstrate its effectiveness and well tolerance by patients, including the children. However, the drug was only approved to use in allergic asthma and chronic spontaneous urticaria (CSU), though other applications were explored in clinical trials. In this review, we summarized current pediatric applications of omalizumab in allergic diseases, focusing on its usages beyond asthma and CSU, including allergic rhinitis, allergic bronchopulmonary aspergillosis, vernal keratoconjunctivitis, food allergy and atopic dermatitis. In addition, we highlighted the unmet needs and controversial issues of anti-IgE therapy.

show abstract

Section: Application Of Omalizumab In Children’s Allergic and Related Diseasesmentioning

confidence: 87%

Pediatric usage of Omalizumab: A promising one

Zhang

Pan

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“…As in CSU [ 52 ], omalizumab has proven safe and effective in adult patients with CIndU [ 53 ]. Therefore, that drug should also be considered at pediatric age for the treatment of more severe cases of ColdU that do not respond to only antihistamine therapy [ 54 ]. In our case series, one or more cycles of omalizumab were administered to seven patients, and all except two of them reported an improvement in ColdU symptoms.…”

Section: Discussionmentioning

confidence: 99%

Cold Anaphylaxis in Children: Italian Case Series and Review of the Literature

Tomei,

Saretta,

Arasi

et al. 2023

Diseases

View full text Add to dashboard Cite

Chronic urticaria (CU) is one of the most common skin disorders worldwide. Among the inducible subgroup of CU, cold urticaria (ColdU) can affect both children and adults and is the only type associated with the risk of anaphylaxis without cofactors. In the scientific literature, data about cold anaphylaxis (ColdA) are poor, especially at pediatric age, and little is known about risk factors associated with the onset of systemic reactions and about the criteria for prescribing adrenaline auto-injectors (AAIs) in these patients. We describe the clinical characteristics and management of a case series of 21 patients with a history of ColdA, and we compare them with the pediatric case reports and case series published so far. On the basis of the scientific literature and of our case series of patients, we suggest that AAI should be prescribed to all high-risk patients: those with urticaria caused by cold-water immersion, oropharyngeal reactions, and with a previous history of systemic symptoms or anaphylaxis.

show abstract

“…Cold urticaria is an unusual form of urticaria whose incidence has been estimated to be 0.05%, being more frequent in young adult women. [1][2][3] The mean duration of the disease is 4-5 years, with remission or improvement of symptoms in 50% of patients within 5 years. 4 Etiopathogenesis of primary acquired cold urticaria is unknown, however can be associated with infectious diseases, malignancies, and food and drug intolerance.…”

mentioning

confidence: 99%